These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Monitoring exposure of nursing and pharmacy personnel to cytotoxic drugs: urinary mutation assays and urinary platinum as markers of absorption. Venitt S; Crofton-Sleigh C; Hunt J; Speechley V; Briggs K Lancet; 1984 Jan; 1(8368):74-7. PubMed ID: 6140425 [TBL] [Abstract][Full Text] [Related]
3. Comparison of methods for the biomonitoring of nurses handling antitumor drugs. Thiringer G; Granung G; Holmén A; Högstedt B; Järvholm B; Jönsson D; Persson L; Wahlström J; Westin J Scand J Work Environ Health; 1991 Apr; 17(2):133-8. PubMed ID: 2047815 [TBL] [Abstract][Full Text] [Related]
4. Mutagenicity of urine from nurses handling cytostatic drugs, influence of smoking. Bos RP; Leenaars AO; Theuws JL; Henderson PT Int Arch Occup Environ Health; 1982; 50(4):359-69. PubMed ID: 6757139 [TBL] [Abstract][Full Text] [Related]
5. Nurses' and pharmacists' exposure to antineoplastic drugs: findings from industrial hygiene scans and urine mutagenicity tests. Labuhn K; Valanis B; Schoeny R; Loveday K; Vollmer WM Cancer Nurs; 1998 Apr; 21(2):79-89. PubMed ID: 9556934 [TBL] [Abstract][Full Text] [Related]
6. [Mutagenic substances in the urine of nurses in an oncological department]. Rørth M; Jørgensen J; Jørgensen V; Knudsen I; Larsen JC; Munck F Ugeskr Laeger; 1983 Feb; 145(7):475-8. PubMed ID: 6845511 [No Abstract] [Full Text] [Related]
7. Re-evaluation of urine mutagenicity of pharmacy personnel exposed to antineoplastic agents. Connor TH; Theiss JC; Anderson RW; Puckett WH; Matney TS Am J Hosp Pharm; 1986 May; 43(5):1236-9. PubMed ID: 3521267 [No Abstract] [Full Text] [Related]
8. Occupational exposure of nursing personnel to antineoplastic agents. Cloak MM; Connor TH; Stevens KR; Theiss JC; Alt JM; Matney TS; Anderson RW Oncol Nurs Forum; 1985; 12(5):33-9. PubMed ID: 3898029 [No Abstract] [Full Text] [Related]
9. The risks of handling cytotoxic drugs. I. Methods of testing exposure. Kaijser GP; Underberg WJ; Beijnen JH Pharm Weekbl Sci; 1990 Dec; 12(6):217-27. PubMed ID: 2091017 [TBL] [Abstract][Full Text] [Related]
10. Genotoxicity assessment in oncology nurses handling anti-neoplastic drugs. Rekhadevi PV; Sailaja N; Chandrasekhar M; Mahboob M; Rahman MF; Grover P Mutagenesis; 2007 Nov; 22(6):395-401. PubMed ID: 17855733 [TBL] [Abstract][Full Text] [Related]
11. Occupational exposure to cytotoxic drugs in two UK oncology wards. Ziegler E; Mason HJ; Baxter PJ Occup Environ Med; 2002 Sep; 59(9):608-12. PubMed ID: 12205233 [TBL] [Abstract][Full Text] [Related]
12. Urinary biological monitoring markers of anticancer drug exposure in oncology nurses. Newman MA; Valanis BG; Schoeny RS; Hee SQ Am J Public Health; 1994 May; 84(5):852-5. PubMed ID: 8179062 [TBL] [Abstract][Full Text] [Related]
13. [Urinary excretion of mutagens and cisplatin among the nursing staff at a medical oncology department exposed to cytostatic drugs]. Clonfero E; Granella M; Gori GP; Venier P; Levis AG; Morandi P; Bartolucci GB; Saia B Med Lav; 1989; 80(5):412-9. PubMed ID: 2622413 [TBL] [Abstract][Full Text] [Related]
14. Mutagenicity assessment of environmental contaminations in a hospital centralized reconstitution unit. Chouquet T; Acramel A; Sauvageon H; Plé A; Jourdan N; Madelaine I; Faure P; Mourah S; Goldwirt L Ecotoxicol Environ Saf; 2018 Dec; 165():174-181. PubMed ID: 30195999 [TBL] [Abstract][Full Text] [Related]
15. Mutagenicity in urine of nurses handling cytostatic drugs. Falck K; Gröhn P; Sorsa M; Vainio H; Heinonen E; Holsti LR Lancet; 1979 Jun; 1(8128):1250-1. PubMed ID: 87722 [No Abstract] [Full Text] [Related]
16. Monitoring mutagenicity in urine and peripheral blood lymphocytes of pharmacists occupationally exposed to anticancer drugs. Elliott G; Ferguson L; Everts R; Edwards R N Z Med J; 1990 Jan; 103(882):13-6. PubMed ID: 2406649 [TBL] [Abstract][Full Text] [Related]
17. Genotoxic risks to nurses from contamination of the work environment with antineoplastic drugs in Japan. Yoshida J; Kosaka H; Tomioka K; Kumagai S J Occup Health; 2006 Nov; 48(6):517-22. PubMed ID: 17179646 [TBL] [Abstract][Full Text] [Related]
18. Urinary mutagenicity assays: a problem arising from the presence of histidine associated growth factors in XAD-2 prepared urine concentrates, with particular relevance to assays carried out using the bacterial fluctuation test. Gibson JF; Baxter PJ; Hedworth-Whitty RB; Gompertz D Carcinogenesis; 1983 Nov; 4(11):1471-6. PubMed ID: 6357523 [TBL] [Abstract][Full Text] [Related]
19. [Determination of urinary genotoxicity: application to the detection of smoking and/or occupational exposure]. Courtois YA; Beaubestre C; Benhamou S; Min S; Callais F; Sancho-Garnier H; Festy B Ann Pharm Fr; 1987; 45(4):289-300. PubMed ID: 3445991 [No Abstract] [Full Text] [Related]
20. A signal assay for the detection of genotoxic compounds: application on the urines of cancer patients on chemotherapy and of nurses handling cytotoxic drugs. Burgaz S; Ozdamar YN; Karakaya AE Hum Toxicol; 1988 Nov; 7(6):557-60. PubMed ID: 3229765 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]